ABSTRACT
macrophage. 21, 22 Consequently, the content of aGal and/or H-antigen on a cell surface may influence the ability of macrophages to recognize cells and facilitate destruction.
Other types of glycosylation may also be involved in rejection. For example, sialylation, which is the addition of a sialic acid group in an a (2, 6) or a (2, 3) linkage to a carbohydrate chain by a sialyltransferase enzyme, is critical in many cell-recognition events. Terminal sialyltransferases act on the same substrate as the FT and GT enzymes, and cells with altered FT or GT activity have been shown to have altered sialic acid levels. [23] [24] [25] Transgenic mice expressing H-antigen, which have reduced aGal levels, show a large decrease in sialic acid content and unexpected binding of human antibodies with specificity other than aGal. 26 The authors proposed that disruption of sialylation caused previously inaccessible epitopes to become accessible to antibodies. Sialic acid expression may also impact the later stage of the immune response involving monocytes. A recent study found reduced monocyte binding to cells which express FT and possess reduced levels of both aGal and sialic acids. 27 The authors concluded that human monocytes bind sialylated surface structures.
Immune modulation
In an attempt to modulate the immune response to xenograft tissue, efforts have concentrated on understanding HAR, while comparatively little work has been devoted to later stages of immune rejection. Most of these studies have focused on interruption of antibody-antigen interactions. Examples include depletion of xenoreactive antibodies by immunoabsorption 28 and administration of soluble antigen 3 to inhibit xenoreactive antibody binding to donor tissue. These techniques, although mildly effective in prolonging xenograft survival, are only temporary solutions.
As a more permanent solution, molecular strategies have been proposed to prevent the addition of aGal to proteins on donor organs. In one approach, homologous recombination was used to knock out the GT gene in mice. 29 Despite their complete lack of aGal, cells from these mice still experienced measurable antibody binding. Others have hypothesized that the absence of GT exposed underlying epitopes that provoked an immune response. 30 Subsequently, others have generated transgenic mice that express the human FT enzyme, and thus express nonimmunogenic H-antigen in place of aGal. [30] [31] [32] A marked reduction in aGal was observed on capillary endothelial cells, but no visible reduction was found on small and medium arteries despite strong expression of H-antigen. Furthermore, cells from these mice showed an unexpected binding of human antibodies, possibly because disruption of sialylation caused previously inaccessible epitopes to become accessible. 26 Researchers have also successfully bred transgenic pigs that express H-antigen in place of aGal 31 or that express proteins that minimize the complement reaction. [33] [34] [35] However, studies to quantitatively assess the reduction in aGal expression and the immune response were not performed.
Work is also being performed to manipulate immunogenic cell surface sugars on isolated cells. Sandrin and co-workers have transfected a porcine fibroblast cell line with the FT gene and noticed an 80% decrease both in aGal levels and in cell lysis mediated by antibodies and complement. 36 They later presented findings which suggest that FT is acting at an earlier stage in the glycosylation pathway than is GT. 37 In another approach, Strahan et al. 38 used antisense DNA against the GT gene in porcine endothelial cells. In this strategy, a short piece of DNA complementary to the GT RNA is introduced into the cell, where it binds the RNA and thereby temporarily blocks production of the GT enzyme and the aGal epitope. This method transiently reduced aGal by 40%. 38 Unfortunately, most other studies on isolated cells have focused on fibroblasts or other nonvascular cells. As endothelium is the primary target for xenograft rejection, it is critical that more studies be performed in these cells. In addition, the role of altered cell surface glycosylation in DXR needs to be more thoroughly addressed.
Present studies
We created an array of xenogeneic cell lines with altered cell surface sugars (Table 1) using the following strategies: (1) transfection of bovine endothelial cells with the gene for the human enzyme, fucosyltransferase (FT), that preferentially adds the nonimmunogenic fucose group (H-antigen) instead of aGal; (2) transfection of cells with antisense (AS) DNA that inhibits the production of the native galactosyltransferase (GT) enzyme that catalyzes the addition of aGal; and (3) cotransfection with both the FT and aGAL MODULATION OF XENOGENEIC ENDOTHELIAL CELLS the antisense GT (ASGT) genes. We investigated whether levels of cell surface sugars correlate to immune rejection events such as antibody binding, complement-mediated cell lysis, and monocyte adhesion. Our studies reveal that the severity of complement-mediated cell lysis, the hallmark of HAR, cannot be fully predicted by aGal levels. Also, our data indicate that neither sialic acids nor aGal are predictors of monocyte adhesion, and that protection from HAR by genetic modification does not necessarily lead to resistance to monocyte adhesion.
MATERIALS AND METHODS

Vector construction
An expression vector was designed for constitutive high-level expression of FT. The human a(1,2)-fucosyltransferase gene was provided in the pCDM7 vector by Dr. John B. Lowe (University of Michigan). The FT gene was excised using HindIII and NotI restriction endonucleases and gel-purified using the QiaQuick gel extraction kit (Qiagen, Valencia, CA). The gene was inserted into the vector pRcRSVneo (Invitrogen, Carlsbad, CA) at the HindIII and NotI polylinker sites to yield pRcRSV/FT. This vector was chosen because it includes enhancer promoter sequences from the Rous sarcoma virus (RSV) long terminal repeat promoter for high-level expression. 39 pRcRSV/FT was transformed into DH5a competent cells (Gibco BRL, Rockville, MD) by heat-shock and grown on agar plates with 60 mg/mL ampicillin. Plasmid DNA was prepped using Qiagen spin minipreps according to manufacturer's instructions. After verification of the correct vector construction by restriction analysis, the vector was transformed again into DH5a and prepped in large quantity using a Qiagen Megaprep kit. The resulting vector was screened by restriction analysis and sequence verified.
A second expression vector was designed to contain an antisense portion of the bovine GT gene, with expression controlled by a high-level cytomegalovirus (CMV) constitutive promoter. The bovine a(1,3)-galactosyltransferase gene in a pBluescript II plasmid was provided by Dr. David H. Joziasse (Vrije Universiteit, Amsterdam). The 59 portion of the GT gene (nucleotides 300-714 of the published sequence 40 ) was excised from the pBluescript plasmid using XbaI and AflII restriction enzymes and inserted in antisense orientation into pcDNA3.1/Hygro (Invitrogen) at its matching polylinker sites using T4 DNA ligase to produce pcDNA3.1/ASGT. The ligation mixture was digested with XhoI and KpnI to cleave unwanted circular products, then transformed into DH5a. The correct miniprep was retransformed, megaprepped, and sequenced to confirm identity.
Note that pRcRSV/FT bears a gene for G418 resistance, whereas pcDNA3.1/ASGT confers resistance to Hygromycin B. Thus, the vectors were able to be stably cotransfected. Parent vectors were used without modification for control transfections.
Cell culture
An immortal bovine aortic endothelial cell line (GM07372A; NIGMS Cell Repository, Bethesda, MD) was chosen for these studies because bovine aortic endothelial cells are well-characterized. Cells were pas- A human monocytic cell line U937 was obtained from the American Type Culture Collection (Rockville, MD) and cultured in RPMI 1640 medium (Sigma) supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate (Sigma), 100 U/mL penicillin, and 100 mg/mL streptomycin sulfate. These cells were subcultured two to three times per week at 1:5 to 1:10 ratios.
Transfection
Transfections were performed to create the FT, AS, and FTAS lines (Table 1) . GM07372A endothelial cells were transfected by calcium phosphate precipitation. 41 Coprecipitation of DNA with calcium phosphate is one of the more commonly used methods for generation of stable transfectants. 42, 43 Transfection efficiency (numbers of cells receiving genetic material) for this method is typically around 2-7%. 43, 44 Specifically, cells were plated to achieve 70% confluency at the time of transfection. Each 100 mm culture dish was transfected for 16 h with 20 mg of linearized DNA. After transfection, the DNA precipitate mixture was removed and the dishes were rinsed twice with PBS and fed with fresh growth medium. After 2 days, the medium was removed and replaced with fresh medium containing the appropriate selective antibiotics: Geneticin (G418; Gibco BRL) at 400 mg/mL and Hygromycin B (Gibco BRL) at 10 mg/mL. Optimum antibiotic concentrations were determined by toxicity testing. Cell death was complete after 7-10 days, at which point cells were passaged at high dilution to allow colony formation. Individual colonies were isolated using cloning cylinders and then propagated and frozen for later analysis. All clones studied were from the same transfection batch.
The respective controls for FT, AS, and FTAS clones, in which cells were transfected with the vector lacking the FT or ASGT gene, were designated neo, hyg, and neo/hyg. Also, cells were taken through the transfection procedure (without subsequent antibiotic selection) with a calcium phosphate mixture that lacked added DNA, yielding the mock transfectants. Flow cytometry results showed equivalent levels of aGal on the mock-transfected cells and the neo, hyg, and neo/hyg transfectant controls. Given these similar results, we chose to use the mock cells as the controls for all experiments. To do otherwise would have required a different control for each type of clone (FT versus AS versus FTAS), and would have made normalization and comparison of results more complex.
Cell surface carbohydrate analysis and antibody binding analysis
Each clone was analyzed using flow cytometry with lectin probes to determine cell-surface levels of aGal and H-antigen. Endothelial cell monolayers were harvested by treatment with 20 mM EDTA (Sigma) and collected in warmed, serum-containing growth medium for counting. The cell suspension was rinsed in cold Hepes-buffered saline containing 0.1 mM Ca 21 and resuspended in Hepes at 2 3 10 6 cells/mL. FITC-conjugated lectins that bind aGal and H-antigen, respectively, were used at the following concentrations: GSL I-B 4 , 80 mg/mL, and UEA I, 20 mg/mL. Lectins were purchased from Vector Laboratories (Burlington, CA). Cells were incubated with the appropriate lectin for 30 min on ice, rinsed in Hepes, and resuspended in fresh Hepes for flow cytometry analysis.
Since cell-surface sialic acid levels can be affected by activities of the GT and FT enzymes, we measured sialic acid content [i.e., a (2, 6) and a(2,3) sialic acid linkages] for each clone. The SNA I FITC-conjugated lectin (Vector Laboratories) at 80 mg/mL was used to stain for a (2, 6) sialic acids. For detection of a(2,3) sialic acids, a biotinylated MAL II lectin (Vector Laboratories) was mixed at 100 mg/mL with cells at 3.2 3 10 6 cells/mL. Oregon Green-NeutrAvidin (Molecular Probes, Eugene, OR) was used as the secondary detection reagent, with 0.1 mg/mL used to stain 4 3 10 6 cells/mL.
Flow cytometry was used to measure human IgM and IgG antibody binding. Binding of human xenoreactive antibodies, which usually precedes complement-mediated cell lysis, is a key step in HAR. Cells were aGAL MODULATION OF XENOGENEIC ENDOTHELIAL CELLS rinsed in cold PBS, then resuspended in heat-inactivated pooled human serum (Pel-Freez, Brown Deer, WI) at 1 3 10 6 cells/mL and kept on ice 30 min. The cells were then rinsed in PBS and resuspended in cold PBS/1% BSA at 5 3 10 6 cells/mL with FITC-conjugated anti-human IgM or anti-human IgG (Sigma) added at 1:16 dilution. The cells were stained 30 min on ice, rinsed in PBS, and resuspended in fresh PBS for flow cytometric analysis.
Flow cytometric analysis was performed on a Becton Dickinson FACSCalibur instrument (BD Immunocytometry Systems, San Jose, CA), with data for at least 10,000 cells collected in each run. Data analysis to determine the geometric mean for each run was performed using CellQuest software. The geometric mean was used in all analyses because the instrument photomultiplier was set at a logarithmic amplification. Photomultiplier settings were selected to yield the most sensitive measure, and thus most quantitative data, by keeping data in the lower half of the 10 0 to 10 4 logarithmic scale.
Galactosyltransferase enzyme activity assay
Galactosyltransferase (GT) enzyme activity was measured for selected AS clones to confirm that transfection with antisense GT effected a reduction in GT activity. Thus, a reduction in aGal in ASGT clones could be attributed to the antisense GT gene. GT activity was measured by the incorporation of UDP-[ 14 C]galactose onto the exogenous N-acetyllactosamine substrate when mixed with a cell extract. GT has a strict specificity for the UDP-galactose substrate. 45 The reaction mixtures (50 mL total volume) contained 100 mM sodium cacodylate (Sigma) pH 6.5, 20 mM MnCl 2 (Sigma), 0.8% Triton X-100, 5 mM ATP (Sigma), 10 mM N-acetyllactosamine (Sigma), 0.0375 mCi [ 14 C]-UDP-galactose (Amersham Pharmacia Biotech, Piscataway, NJ), and 20 mg of cell extract. The mixture was incubated 30 min at 37°C; then the reaction was stopped with 50 mL of absolute ethanol and 1 mL of water. This diluted mixture was passed through a Pasteur pipette column of Dowex 1X-800 anion exchange resin (Sigma) over glass wool, equilibrated with water. The eluate was collected into a scintillation vial containing 15 mL of ScintiSafe 30% scintillation cocktail (Fisher Scientific, Pittsburgh, PA). Each lysate was run in duplicate or triplicate along with a control in which no exogenous N-acetyllactosamine was added, to account for the presence of acceptor molecules in the cell extract.
Cell extracts used in the above assay were obtained from cells at confluency. Briefly, cell layers were rinsed twice in cold PBS, then scraped into cold PBS with added protease inhibitors (aprotinin at a working concentration of 1 mg/mL, antipain at 1 mg/mL, pepstatin A at 1 mg/mL, leupeptin at 2 mg/mL, and PMSF at 100 mg/mL; all from Sigma). The cell suspension was centrifuged and the cell pellet was resuspended in 100 mM sodium cacodylate buffer (pH 6.5) containing 1% Triton X-100 (Sigma) and protease inhibitors and kept on ice for 30 min, followed by centrifugation for 30 min at 10,000g and 4°C. The supernatant was aliquoted and stored at 285°C. Total protein concentration of each extract was determined by the bicinchoninic acid (BCA) protein assay, run in triplicate.
Complement-mediated cell lysis assay
Complement-mediated cell lysis was measured for selected clones to assess the susceptibility of each clone to the HAR rejection phase. Briefly, cells were subjected to human serum which has had its native complement inactivated by heat treatment, followed by an incubation with rabbit complement to effect lysis of cells that have been sufficiently bound by antibody in the human serum. Commercial processing of human serum does not sufficiently preserve the complement activity for use in an in vitro assay; thus, heatinactivated human serum is coupled with rabbit complement, which is readily available and of high activity, as the components which give the most consistent in vitro assay results. Endothelial cell monolayers were harvested at confluency with 20 mM EDTA. Cells were collected in warm, serum-containing MEM, centrifuged, then resuspended in Eagle's MEM supplemented with glutamine, nonessential amino acids, and 2 3 MEM vitamins (MEM11). Aliquots of 3 3 10 5 cells were transferred to microcentrifuge tubes. After centrifugation, the cells were resuspended in heat-inactivated human serum at 1 3 10 6 cells/mL at twofold serum dilutions beginning at 1:8. Cells were kept on ice 30 min, then centrifuged, rinsed in warm MEM11, and centrifuged again. Cells were then resuspended at 1 3 10 6 cells/ml in LowTox-H rabbit complement (Cedarlane Laboratories, Hornby, Ontario Canada) diluted 1:4 in MEM11 and incubated at 37°C for 30 min. Cells were rinsed twice with MEM11, and counts were performed using trypan blue exclusion. At least 300 cells were counted for each sample and the percent death determined by the ratio of dead cells to total cells, subtracting the percent cell death due to complement treatment alone.
Monocyte adhesion assay
Clones were analyzed to discern whether cell-surface carbohydrate levels correlated with monocyte binding as a predictor of DXR. To collect data in sufficient quantities with limited variability, a human monocytic cell line (U937 cell line) was used for the studies. The results obtained with the cell line were verified with limited studies using fresh human peripheral blood monocytes.
Endothelial cells were inoculated into 96-well tissue culture dishes at 1.5 3 10 4 to 2 3 10 4 cells/well 18-22 h before the assay, to just achieve confluency at the time of the assay. Prior to the assay, three wells of each clone were detached with trypsin-EDTA (Gibco-BRL) and counted using a hemacytometer. U937 monocytic cells in growth phase were harvested, counted, and resuspended in 10 mM calcein AM viability stain (Molecular Probes) in PBS at 2 3 10 6 cells/mL. The cell suspension was incubated at 37°C/5% CO 2 for 30 min to load the cells with dye. The loaded U937 cells were rinsed with RPMI growth medium and brought to 8:1 effector/target (i.e., monocyte/endothelial cell) ratios in fresh RPMI growth medium containing 50 ng/mL phorbol myristate acetate (PMA; Sigma). PMA treatment can enhance binding of U937 cells to endothelial cells, and is thought to stimulate the development of macrophage-like properties in U937 cells. 46 The U937 suspensions were applied at 100 mL/well to endothelial cell wells (in triplicate) that had been rinsed twice with RPMI growth medium. RPMI/PMA was applied as a negative control. After a 45-min incubation at 37°C/5% CO 2 , the wells were rinsed four times with RPMI growth medium to remove nonadherent U937 cells. Fluorescence from the remaining adherent U937 cells was quantitated using a FluorImager fluorescence scanner (Molecular Dynamics, Sunnyvale, CA) and ImageQuaNT analysis software. Microscopy was used to confirm U937 adhesion to the endothelial cells.
For fresh human monocyte binding studies, peripheral blood mononuclear cells (PBMC) were isolated from blood obtained from healthy volunteers. Venous blood was collected in lithium heparin and fractionated within 1 h on Histopaque-1077 (Sigma). A layer of 12-15 mL of blood was gently placed over 10 mL of Histopaque and centrifuged (6 min, 1,300g) at room temperature. The interface containing PBMC was collected and washed three times with Hank's balanced salt solution (HBSS) and cells were counted using trypan blue. PBMC were resuspended at 1 3 10 7 viable cells/mL in RPMI growth medium. Further purification of the monocytes from the PBMC was obtained by allowing the monocytes to adhere to a tissue culture dish at 37°C/5% CO 2 for 45-60 min. Nonadherent cells were removed by aspiration and the remaining cells (monocytes) were rinsed twice with HBSS, detached with trypsin-EDTA, washed and resuspended in RPMI medium. Monocytes were incubated at 37°C for 4-5 h prior to the assay. The assay was performed as above.
Statistical analysis
All experiments were performed at least three times and plotted with error bars representing the standard error of the mean. Significance testing between means was performed using the t test, comparing each clone value to that of the control. The cut-off for statistical significance is p , 0.05.
RESULTS
Analysis of GT activity and H-antigen expression
To verify that newly introduced genetic material was affecting cellular processes, activities of the antisense GT gene and the human FT gene were analyzed. First, GT enzyme activity was measured and compared to that present in control cells to confirm that AS clones possessed an active antisense GT gene, as determined by decreased GT enzyme activity. As predicted, transfection with antisense GT did result in reduced GT enzyme activity compared to that for mock cells and cells transfected with the FT gene only (Fig.  2) . For the FT transfectants, the FT gene was added to produce the FT enzyme which competes with GT aGAL MODULATION OF XENOGENEIC ENDOTHELIAL CELLS for the same substrate (ideally, to reduce aGal expression). However, the GT levels should remain unaffected since the production of GT itself is not altered. On the other hand, the AS clones involve the addition of an antisense gene for the GT enzyme itself, resulting in lowered levels of GT. The GT activity in the FTAS13 clone is not as dramatically reduced as that for AS22, AS23 and FTAS6; however, it is statistically lower than the GT activity for the mock cells. It is possible that the FTAS13 clone had fewer copies of the ASGT gene compared to the other AS and FTAS clones. As expected, human endothelial cell controls (HUVECs) exhibited negligible activity due to their lack of a functional GT gene.
To identify clones with an active human FT gene, the cell-surface product of the FT enzyme, H-antigen, was measured. Flow cytometry measured H-antigen on clones transfected with the FT gene, but not on mock cells or AS clones transfected with the antisense GT gene only (Fig. 3) .
Cell surface expression of aGal and sialic acids
To assess the effect of the FT and AS genetic manipulations on the levels of cell-surface carbohydrates possibly involved in the rejection process, flow cytometric measurements of aGal and a (2, 3) and a (2, 6) FIG. 2. Antisense GT gene reduces GT enzyme activity. Galactosyltransferase enzyme activity was measured for clone extracts to confirm that transfection with ASGT effected a reduction in GT activity. GT activity was measured by the incorporation of UDP-[ 14 C]galactose into the exogenous N-acetyllactosamine substrate when mixed with cell extract. The histogram represents the incorporated counts per minute (CPM), corrected for nonspecific effects, for selected clones and the mock and human endothelial cell (HUVEC) controls. The data shown are averages of at least eight independent measurements, performed on at least three different batches of cell extracts. ASGT clones show varying but significant reductions in GT activity. Asterisks represent data that are statistically distinct from the mock control (p , 0.05).
FIG. 3.
H-antigen is present on cells transfected with the human FT gene. Detection of H-antigen was performed using a fluorescently tagged lectin specific for the H-antigen epitope. Shown is the logarithmic mean fluorescence intensity as determined by flow cytometry of at least 10,000 cells per sample, for at least five independent measurements on separate days. The positive intensities of FT and FTAS clones indicate the presence of H-antigen on the cell, whereas mock and AS clones were not transfected with the FT gene and do not express the H-antigen epitope. Asterisks represent data that are statistically distinct from the mock control (p , 0.05).
sialic acids were conducted. Expression levels of aGal were reduced by 10-20% in most clones (Fig. 4) . Surprisingly, the AS23 clone showed no reduction in aGal, despite the dramatic decrease in GT enzyme activity (Fig. 2) . Overall, endothelial cells are known to have much higher aGal expression levels compared to other cell types. 20 Thus, even a strong RSV or CMV promoter, as used in these studies, may not produce as large a reduction in aGal as observed in other cells. 36 As a result, aGal reduction obtained in these studies was in fact smaller than anticipated.
Sialic acid in the a(2,3) linkage did not display significant differences among clones relative to the mock-transfected cells (data not shown). However, a(2,6) sialic acids did exhibit significant changes (Fig. 5) . Both FT and FTAS transfectants had reduced levels of a (2, 6) sialic acids compared to mock cells, whereas AS clones showed similar or elevated levels compared to mock cells. These data suggest that a(2,6) sialic acid is primarily influenced by FT, and that several glycosyltransferases compete for limited substrate. For example, if an additional glycosyltransferase is introduced, sialyltransferases will be allotted less substrate and levels of cell-surface sialic acid may drop. Similarly, if activity of GT is reduced, sialyltransferases may have access to more substrate and create more cell-surface sialic acids.
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FIG. 4.
Cell surface aGal levels are reduced in most clones. Detection of aGal was performed using a fluorescently tagged lectin specific for aGal. Shown is the logarithmic mean fluorescence intensity as determined by flow cytometry of at least 10,000 cells per sample, for at least five independent measurements on separate days. Asterisks represent data that are statistically distinct from the mock control (p , 0.05).
FIG. 5. a(2,6)
Sialic acids exhibit changes as a result of FT and ASGT genes. Detection of a(2,6) sialic acids was performed using a fluorescently tagged lectin specific for the a(2,6) sialic acid linkage. Shown is the logarithmic mean fluorescence intensity as determined by flow cytometry of at least 10,000 cells per sample, for at least five independent measurements on separate days. Both FT and FTAS transfectants had reduced levels of a(2,6) sialic acids, whereas AS clones showed elevated levels. These data suggest that several glycosyltransferases compete for limited substrate. Asterisks represent data that are statistically distinct from the mock control (p , 0.05).
To determine whether there is a quantitative relationship between cell-surface carbohydrates and the first stage of xenograft rejection, the genetically modified clones were analyzed for their tendency to bind antibodies in human serum and be lysed by the addition of complement after incubation with antibodies. The binding of transfectant cell lines by human IgM mirrors levels of aGal, as expected (Fig. 6) .
However, lysis by complement does not show the same relationship to aGal levels. Despite small reductions in aGal, most clones had significant protection from complement-mediated cell lysis (Fig. 7) . The AS23 clone, in fact, exhibits no reduction in aGal or in IgM binding, yet shows a significant protection from lysis by complement. In the opposite situation is FTAS6, a clone which has reduced aGal and reduced IgM binding but no protection from lysis. These data suggest the possible presence of one or more additional epitopes mediating this response. Also, it has been shown that activation of endothelial cells can result in changes in transcriptional and posttranscriptional regulation of GT, which subsequently results in modulated (decreased) aGal levels. 47 Thus, these studies could in part be complicated by varying degrees of activation.
FIG. 6.
Binding of human IgM is reduced for most clones. Clones were analyzed for their tendency to bind antibodies present in human serum. Antibody binding was assessed by incubating cells with human serum, followed by incubation with fluorescently tagged anti-human IgM. Shown is the logarithmic mean fluorescence intensity as determined by flow cytometry of at least 10,000 cells per sample, for at least five independent measurements on separate days. Human IgM binding to the clones represents the first event in rejection and mirrors levels of aGal, as expected. Asterisks represent data that are statistically distinct from the mock control (p , 0.05).
FIG. 7.
Complement-mediated cell lysis does not vary directly with aGal levels. Cells were harvested and incubated with human serum, followed by rabbit complement. Percent lysis of a cell suspension was then determined by trypan blue exclusion, counting at least 300 cells per sample. Averages shown were determined from at least four different samples on separate days. Most clones had significant protection from complement-mediated cell lysis, but this protection did not correlate with aGal levels, suggesting the possible presence of one or more additional epitopes mediating this response. Asterisks represent data that are statistically distinct from the mock control (p , 0.05).
Adhesion of U937 monocytic cells to clones
To determine whether one or more known cell-surface carbohydrates is responsible for binding human monocytes in later stages of xenograft rejection (i.e., DXR), binding experiments were carried out with the clones and human monocytic cell line U937. Binding of human monocytic cells to antisense GT transfectants was significantly higher than binding to mock-transfected cells (Fig. 8) . In contrast, cells transfected with both FT and antisense GT showed significantly reduced binding of U937 cells. When SNA I lectin was incubated with the clones prior to co-incubation with U937 cells, to block a(2,6) sialic acid residues, no effect was seen, indicating that a(2,6) sialic acids are not the key epitope in monocyte adhesion (data not shown). To confirm the validity of these results in nontransformed cells, these adhesion experiments were repeated with freshly isolated human peripheral blood monocytes. Results were similar (data not shown).
DISCUSSION
Tissue engineered products have the potential to revolutionize medical treatment for afflictions rooted in loss of tissue function. However, because the functioning of the living cells in the tissue-engineered product is central to a successful medical outcome, the question of a cell source is paramount. While each clinical application may find a unique approach to meeting the need for a safe and effective source of cells, in at least some situations the use of nonhuman cells may be the best course of action. Indeed, animal cell lines can be a readily-available, well-characterized source of cells. Taking steps toward making animal cell transplantation predictable and safe could open the doors to many more life-saving tissue-engineered products.
First, more knowledge of the xenograft rejection process-and the molecules that mediate it-is needed. While many studies have explored the role of aGal in hyperacute xenograft rejection, quantitative correlations defining the roles of multiple cell-surface carbohydrates in rejection events are lacking. With this work, we sought to use a unique experimental system composed of many genetically engineered cell lines to extend our knowledge of the role of cell-surface carbohydrates in both immediate and later stages of rejection.
Previously, aGal was thought to be a primary epitope to elicit immune responses. The studies presented here indicate that additional epitopes may be involved in mediating rejection. Two different clones support this hypothesis. First, AS23 has undiminished aGal levels and is bound by human IgM at the same level as control cells, yet shows protection from lysis by complement. This clone may be deficient in an epitope which promotes immune attack. Second, FTAS6 has no protection from complement-mediated lysis despite its reduced levels of aGal and IgM binding. The experimental procedure was controlled for the possible presence of antibodies in the rabbit complement preparation, so the lysis is due to specific human recognition of what must be an additional xenoepitope. In both cases, we conclude from the results that one or more epitopes other than aGal may influence the complement-mediated lysis rejection response.
Our data also strongly suggest that antibodies, as instigators in the complement response, and monocytes appear to be recognizing different cell surface epitopes. The antisense GT clones with elevated monocyte binding exhibit reduced complement-mediated lysis, whereas one clone (FTAS6) with reduced monocyte binding exhibits undiminished susceptibility to complement.
Despite the advances in modification of pigs for the avoidance of xenograft rejection, our studies illustrate that certain modifications which confer protection against complement-mediated cell lysis may cause a more severe reaction with cellular immune mediators, or vice versa. Engineering a cell line to function in a living graft without immunogenicity is a complex task.
Furthermore, the correlation between aGal expression and some of the functional studies are not as strong as we would have predicted, and there was some degree of variability between the clones. We feel that this variability is important to report since it provides an indication of the complications that can arise when attempting to engineer cells, especially their carbohydrate moieties, for eventual tissue engineering applications. Part of this could be a result of the difference in species (bovine) used for this study compared to the data reported in the literature predominantly for porcine cells and tissues. It is possible that aGal plays less of a role in bovine-to-human rejection, compared to the porcine-to-human response. Leaders in the field agree that most current research is only strictly applicable to pig-to-human rejection. 20 Furthermore, it is recognized and has been shown to some extent that aGal expression patterns vary from species to species. 20, 48 Future work in this area will focus on the identification of additional xenoepitopes, especially those created, exposed, or made accessible by transfection with glycosyltransferase genes. By adding individual mono-and polysaccharides to antibody or monocyte binding experiments, the ability of one or more of these sugars to block important interactions can be noted. Using this approach, we can identify which sugars are most successful at blocking important interactions, thus clarifying at the molecular level the recognition event which governs that part of the immune response.
